Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;20(8):980-984.
doi: 10.1111/1756-185X.12605. Epub 2015 May 27.

Association of HLA-B*27 with ankylosing spondylitis in Kurdish patients

Affiliations

Association of HLA-B*27 with ankylosing spondylitis in Kurdish patients

Rawand Al-Qadi et al. Int J Rheum Dis. 2017 Aug.

Abstract

Objective: To investigate the prevalence of human leukocyte antigen (HLA)-B*27 among a healthy Kurdish population and in patients with ankylosing spondylitis.

Methods: The prevalence of HLA-B*27 was investigated in 209 healthy donors recruited from the Kurdistan Region of Iraq, and in 41 diagnosed ankylosing spondylitis patients. The HLA statuses for the patients and healthy donors were determined by using the low-resolution Olerup SSP® HLA typing kits.

Results: We observed that the prevalence of HLA-B*27 in healthy Kurdish donors was 3.8% (8/209). While the prevalence of HLA-B*27 in patients with ankylosing spondylitis was 65.9% (27/41 studied) with a P-value of < 0.01. The relative risk of having the disease is 12 times higher in individuals with HLA-B*27 compared to those who do not have it. The male-to-female ratio was 5.8 : 1 in HLA-B*27 positive patients. The disease onset is earlier in HLA-B*27-positive patients.

Conclusion: From this study, we can conclude that the prevalence of HLA-B*27 among the Kurdish healthy population is 3.8% and there is a strong association between HLA-B*27 and ankylosing spondylitis patients in the Kurdistan Region of Iraq.

Keywords: HLA-B*27; ankylosing spondylitis; spondyloarthritis.

PubMed Disclaimer

MeSH terms

Substances